Literature DB >> 25018000

Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.

Hendrik A M Swellengrebel1, Steven L Bosch2, Annemieke Cats3, Andrew D Vincent4, Luc G H Dewit5, Vic J Verwaal6, Iris D Nagtegaal2, Corrie A M Marijnen7.   

Abstract

BACKGROUND: After preoperative chemoradiotherapy (CRT) for rectal cancer, clinically undetectable residual tumour deposits or pathologic lymph nodes may remain in the mesorectum. AIM: The aim of this study was to report histopathological effects of CRT and factors affecting outcome in a uniformly treated series of locally advanced rectal cancer (LARC) patients.
METHODS: Between 2004 and 2008, 107 patients with cT3 (threatening the mesorectal fascia or <5 cm from the anal verge), cT4 or cN2 rectal cancer were treated with preoperative CRT (25 × 2 Gy with capecitabine) and TME 6-8 weeks later. Central histopathological review followed. Tumour regression grade (TRG) was scored in pCR, near-pCR, response and no response. Cox regression was performed to identify prognosticators.
RESULTS: The 3-year distant metastasis-free interval, disease-free rate and overall survival rate were 82%, 73% and 87% (median 44 months follow-up). TRG consisted of 20% pCR, 11% near-pCR, 55% response and 14% no response. 6/21 pCR patients harboured nodal metastases. 5/12 near-pCR had ypT3 disease, while 6 harboured node metastases. 5/12 near-PCR patients developed distant metastases. ypN and TRG were powerful outcome discriminators.
CONCLUSION: The high number of near-pCR with ypT3 or ypN1/2 and their poor outcome demonstrates that "watch-and-wait" in LARC patients should be applied with care.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; Outcome; Rectal cancer; Tumour regression grade

Mesh:

Substances:

Year:  2014        PMID: 25018000     DOI: 10.1016/j.radonc.2014.05.010

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  16 in total

Review 1.  Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy.

Authors:  Rupert Langer; Karen Becker
Journal:  Virchows Arch       Date:  2017-09-16       Impact factor: 4.064

Review 2.  'Watch and wait' in rectal cancer: summary of the current evidence.

Authors:  Jason On; Emad H Aly
Journal:  Int J Colorectal Dis       Date:  2018-07-05       Impact factor: 2.571

Review 3.  Watch and wait approach to rectal cancer: A review.

Authors:  Marcos E Pozo; Sandy H Fang
Journal:  World J Gastrointest Surg       Date:  2015-11-27

4.  Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer.

Authors:  Feby Ingriani Mardjuadi; Javier Carrasco; Jean-Charles Coche; Christine Sempoux; Anne Jouret-Mourin; Pierre Scalliet; Jean-Charles Goeminne; Jean-François Daisne; Thierry Delaunoit; Peter Vuylsteke; Yves Humblet; Nicolas Meert; Marc van den Eynde; Anne Moxhon; Karin Haustermans; Jean-Luc Canon; Jean-Pascal Machiels
Journal:  Target Oncol       Date:  2014-10-11       Impact factor: 4.493

5.  Pathological Assessment of Rectal Cancer after Neoadjuvant Chemoradiotherapy: Distribution of Residual Cancer Cells and Accuracy of Biopsy.

Authors:  Lin Xiao; Xin Yu; Wenjing Deng; Huixia Feng; Hui Chang; Weiwei Xiao; Huizhong Zhang; Shaoyan Xi; Mengzhong Liu; Yujia Zhu; Yuanhong Gao
Journal:  Sci Rep       Date:  2016-10-10       Impact factor: 4.379

Review 6.  Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales.

Authors:  Muhammed R S Siddiqui; Jemma Bhoday; Nicholas J Battersby; Manish Chand; Nicholas P West; Al-Mutaz Abulafi; Paris P Tekkis; Gina Brown
Journal:  World J Gastroenterol       Date:  2016-10-07       Impact factor: 5.742

7.  Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery?

Authors:  Luca Reggiani Bonetti; Simona Lionti; Federica Domati; Valeria Barresi
Journal:  World J Gastroenterol       Date:  2017-02-28       Impact factor: 5.742

8.  Influence of Preoperative Chemoradiotherapy on the Surgical Strategy According to the Clinical T Stage of Patients With Rectal Cancer.

Authors:  In Ja Park; Jong Lyul Lee; Yong Sik Yoon; Chan Wook Kim; Seok-Byung Lim; Jong Seok Lee; Seong Ho Park; Jin Hong Park; Jong Hoon Kim; Chang Sik Yu; Jin Cheon Kim
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

9.  Is Pathologic Near-Total Regression an Appropriate Indicator of a Good Response to Preoperative Chemoradiotherapy Based on Oncologic Outcome of Disease?

Authors:  Jee Yeon Kim; In Ja Park; Seung Mo Hong; Jong Lyul Lee; Yong Sik Yoon; Chan Wook Kim; Seok-Byung Lim; Jung Bok Lee; Chang Sik Yu; Jin Cheon Kim
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

10.  Predictors of Pathologic Complete Response in Rectal Cancer Patients Undergoing Total Mesorectal Excision After Preoperative Chemoradiation.

Authors:  Yoon Dae Han; Woo Ram Kim; Seung Wan Park; Min Soo Cho; Hyuk Hur; Byung Soh Min; Seung Hyuk Baik; Kang Young Lee; Nam Kyu Kim
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.